tiprankstipranks
Trending News
More News >
Immucell (ICCC)
:ICCC
Advertisement

Immucell (ICCC) Price & Analysis

Compare
77 Followers

ICCC Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

1.58%3.58%0.18%91.58%
0.18% Other Institutional Investors
91.58% Public Companies and
Individual Investors

ICCC FAQ

What was Immucell’s price range in the past 12 months?
Immucell lowest stock price was $3.34 and its highest was $7.60 in the past 12 months.
    What is Immucell’s market cap?
    Immucell’s market cap is $62.81M.
      When is Immucell’s upcoming earnings report date?
      Immucell’s upcoming earnings report date is Aug 14, 2025 which is in 20 days.
        How were Immucell’s earnings last quarter?
        Immucell released its earnings results on May 14, 2025. The company reported $0.161 earnings per share for the quarter, beating the consensus estimate of N/A by $0.161.
          Is Immucell overvalued?
          According to Wall Street analysts Immucell’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Immucell pay dividends?
            Immucell does not currently pay dividends.
            What is Immucell’s EPS estimate?
            Immucell’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Immucell have?
            Immucell has 9,037,397 shares outstanding.
              What happened to Immucell’s price movement after its last earnings report?
              Immucell reported an EPS of $0.161 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.943%.
                Which hedge fund is a major shareholder of Immucell?
                Currently, no hedge funds are holding shares in ICCC

                Company Description

                Immucell

                Immucell (ICCC) is a biotechnology company operating in the animal health industry. It focuses on developing, manufacturing, and selling products that provide solutions for the prevention and treatment of diseases in livestock, primarily targeting the dairy and beef cattle markets. The company specializes in creating immune-based products that enhance animal health and productivity, with its flagship product being a first-of-its-kind USDA-licensed scours preventative for newborn calves.

                ICCC Company Deck

                ICCC Earnings Call

                Q1 2025
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The earnings call highlighted strong sales growth, improved gross margins, and significant adjusted EBITDA performance, driven by increased production capacity and product line expansion. However, challenges remain with FDA licensing for Re-Tain and managing backlog, alongside potential sales variability due to seasonality.Read More>
                Similar Stocks
                Company
                Price & Change
                Follow
                Adicet Bio
                Werewolf Therapeutics
                Artiva Biotherapeutics, Inc.
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis